Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study

Gary S Collins and Douglas G Altman
BMJ: British Medical Journal
Vol. 340, No. 7758 (5 June 2010), p. 1231
Published by: BMJ
Stable URL: http://www.jstor.org/stable/40701839
Page Count: 1
  • Read Online (Free)
  • Subscribe ($19.50)
  • Cite this Item
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
Preview not available

Abstract

STUDY QUESTION Does QRISK2 provide an improvement over the NICE version of the Framingham risk score for predicting the 10-year risk of cardiovascular disease in the United Kingdom? SUMMARY ANSWER Yes, QRISK2 is more accurate in identifying a high risk population for cardiovascular disease in the United Kingdom than the NICE version of the Framingham equation. WHAT IS KNOWN AND WHAT THIS PAPER ADDS Cardiovascular risk prediction in the United Kingdom has until recently been based on a NICE adjusted version of the US Framingham model that has been shown to over-predict risk. Independent evaluation of QRISK2 shows better performance than NICE Framingham in a large external cohort of UK patients, where QRISK2 identified a group of high risk patients who went on to experience more cardiovascular events over the next 10 years than a similar high risk group identified by NICE Framingham.

Page Thumbnails

  • Thumbnail: Page 
1231
    1231